Acute Pain

Study Descriptions

Schroer et al was a randomized, double-blind, placebo-controlled study in patients undergoing elective unilateral total knee arthroplasty (TKA) to evaluate any rehabilitation benefits of CELEBREX therapy for 6 weeks after the TKA (N=107). CELEBREX 400 mg was given to each patient before surgery and daily throughout their hospitalization with as needed morphine through a patient-controlled analgesia system on the night of surgery. All patients were placed on oral narcotics the morning after surgery. At hospital discharge, patients were randomized to either CELEBREX 200 mg BID or placebo for 6 weeks. All patients had a prescription for oral narcotics as needed. Primary end point was narcotic use (total pill count), and secondary measures included knee pain during activity and at rest, as measured by a visual analog scale (VAS), and Oxford Knee Score.

Back to top

Ekman et al (2006) was a 36-hour, randomized, parallel-group, double-blind, placebo-controlled study to compare total opioid analgesic use at 24 hours after arthroscopic meniscectomy of the knee (primary end point). Patients received CELEBREX 400 mg administered approximately 1 hour before surgery and CELEBREX 200 mg administered at the first request for pain medication after surgery, or placebo. Postsurgery patients were allowed to take 1 to 2 hydrocodone/acetaminophen (APAP) tablets every 4 to 6 hours as rescue medication. Secondary end points included patients' assessment of pain at rest and at 90° flexion using a 0- to 100-mm visual analog scale (VAS). Improvement in patients' assessment of pain at 90° flexion at 8, 10, and 12 hours confirmed in a replicate study. CELEBREX significantly reduced postsurgical knee pain at rest at 10 and 12 hours in the same 2 studies.

Back to top

Ekman et al (2002) was a 10-day, multicenter, double-blind, randomized, parallel-group, placebo-controlled trial to evaluate the efficacy and tolerability of CELEBREX, ibuprofen, or placebo in the treatment of moderate-to-severe acute pain (at least 45 mm on a 100-mm VAS) in 445 adult patients with grade 1 or grade 2 ankle sprain. Patients were randomized to CELEBREX 200 mg BID, ibuprofen 800 mg TID, or placebo. The first dose of study medication was taken as soon as possible after randomization and within 48 hours of injury. Treatment with rest, ice, compression, and elevation (RICE) and physical therapy was permitted; analgesia other than the study medication was not. The study was powered to detect differences between CELEBREX and placebo and to establish noninferiority vs ibuprofen. Primary end points (evaluated on day 4) were pain rating using the patient's assessment of ankle pain on a visual analog scale (VAS) and severity based on the patient's global assessment of ankle injury. Secondary end points included: pain rating using the patient's assessment of ankle pain on a VAS on days 8 and 11; severity based on the patient's global assessment of ankle injury on days 8 and 11; median time to return to normal function/activity or to improve by at least 2 grades.

Back to top

*Eligibility required. Terms and conditions apply. Full terms and conditions can be found at CELEBREX.com/savings-terms. This Savings Offer will be accepted only at participating pharmacies. This Savings Offer is not health insurance. No membership fees. Maximum savings of $1,750 per offer. This Savings Offer is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs. This Savings Offer is not valid for prescriptions that are eligible to be reimbursed in whole by private insurance plans or other health or pharmacy benefit programs. Pfizer reserves the right to revoke, rescind, or amend this offer without notice. For help with the CELEBREX Savings Offer, call 1-855-612-1956, visit CELEBREX.com, or write: Pfizer Inc., 235 E 42nd Street, New York, NY 10017.

References:
  1. Schroer WC, Diesfeld PJ, LeMarr AR, Reedy ME. Benefits of prolonged postoperative cyclooxygenase-2 inhibitor administration on total knee arthroplasty recovery: a double-blind, placebo-controlled study. J Arthroplasty. 2011;26(6 suppl):2-7.
  2. Ekman EF, Wahba M, Ancona F. Analgesic efficacy of perioperative celecoxib in ambulatory arthroscopic knee surgery: a double-blind, placebo-controlled study. Arthroscopy. 2006;22(6):635-642.
  3. Data on file. Pfizer Inc., New York, NY.
  4. Ekman EF, Fiechtner JJ, Levy S, Fort JG. Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain. Am J Orthop. 2002;31(8):445-451.

Back to top